By Billy Candra 
This revolutionary diagnostic approach, detailed in a new study published today in the prestigious journal Neuro-Oncology, represents a monumental leap forward in neuro-oncology. Developed through a collaborative effort between scientists at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH), the method promises to drastically reduce the agonizing wait times for patients and facilitate earlier, more targeted treatment interventions.
A Critical Breakthrough in Brain Tumour Diagnosis
Brain tumours remain one of the most challenging cancers to diagnose and treat, largely due to their intricate nature and the critical location within the central nervous system. The urgency of an accurate diagnosis cannot be overstated, particularly given the aggressive pathology of many brain cancers, where average survival rates can be less than a year. The traditional diagnostic pathway has been fraught with delays, often leaving patients and their families in a state of prolonged anxiety and uncertainty.
The groundbreaking method developed in Nottingham addresses this critical bottleneck directly. For the first time, a comprehensive genetic classification of brain tumours can be achieved with unprecedented speed, moving from a multi-week process to one that delivers actionable results within hours. This efficiency is not merely a matter of convenience; it is a life-saving innovation that could transform the treatment landscape for thousands of individuals diagnosed annually in the UK.
The Current Landscape: Delays and Distress
Each day, 34 people in the UK receive the life-altering diagnosis of a brain tumour, accumulating to more than 12,000 new cases every year. These diagnoses necessitate complex genetic tests to accurately classify the tumour type and predict its behaviour. Historically, these crucial tests have been conducted in centralised analysis facilities, to which tissue samples are dispatched after surgical removal. The logistical and technical complexities involved mean that patients often face a harrowing wait of six to eight weeks, or even longer, before receiving a full diagnosis and prognosis.
This protracted waiting period carries significant emotional and clinical burdens. For patients, it translates into weeks of intense stress, fear, and uncertainty, hindering their ability to plan for the future or come to terms with their condition. From a medical perspective, these delays can have dire consequences, postponing the initiation of vital treatments such as radiotherapy and chemotherapy. Every week lost in starting treatment can potentially diminish its efficacy, thereby reducing the patient’s chances of successful intervention and improved outcomes. The standard pathway begins with an MRI scan to detect a tumour, followed by discussions with clinicians about potential diagnoses. A surgical biopsy is then typically performed to obtain a tissue sample, which is subsequently sent to laboratories for DNA analysis to identify genetic abnormalities crucial for classification.
From Weeks to Hours: The Nottingham Innovation
The Nottingham team’s ultra-rapid genetic diagnostic method promises to eliminate these systemic delays. The core innovation lies in its speed and integration, allowing for results to be generated so quickly that they could potentially be made available to the surgeon during the operation itself, informing real-time surgical decision-making.
Dr. Stuart Smith, a distinguished Neurosurgeon from the School of Medicine at the University of Nottingham and NUH, underscores the profound impact of this development. "Traditionally, the process of diagnosing brain tumours has been slow and expensive," Dr. Smith explains. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision-making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time." He further elaborates on the intraoperative potential: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This ability to tailor surgical approaches based on immediate genetic information represents a paradigm shift, allowing for more precise and effective tumour removal while minimizing damage to healthy brain tissue.
The Science Behind the Speed: Nanopore Sequencing and ROBIN
The breakthrough is rooted in advanced genomic sequencing technology, spearheaded by Professor Matt Loose, a biologist from the School of Life Sciences at the University of Nottingham. Professor Loose developed a method to sequence specific parts of human DNA at higher depth using portable sequencing devices from Oxford Nanopore Technologies. This innovative approach allows researchers to examine relevant sections of the human genome much more quickly and to sequence multiple DNA regions simultaneously, dramatically accelerating the entire diagnostic process.
Professor Loose’s prior work in 2018 demonstrated the feasibility of sequencing an entire human genome, albeit over six months and involving five laboratories. This new method represents a focused evolution, enabling researchers to selectively target and analyse only the critical DNA segments necessary for tumour classification and treatment guidance. "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated," Professor Loose elaborates.
The technological cornerstone of this rapid diagnosis is "ROBIN," a sophisticated software tool designed to interface with P2 PromethION nanopore sequencers. These devices operate by detecting changes in electrical current as single molecules of DNA pass through a nanopore – an infinitesimally small hole – in a membrane. Each change in current corresponds to a specific DNA base, allowing for rapid and accurate sequencing. The team has successfully applied this method to genetically test brain tumour samples, achieving a 100% success rate in 50 brain tumour surgeries. Diagnostic results were consistently provided in under two hours from surgery, with detailed tumour classifications emerging within minutes of sequencing. Furthermore, the platform’s continuous sequencing capability allows for a fully integrated diagnosis to be completed within 24 hours, providing an exhaustive genetic profile.
Once a tissue sample is removed during surgery, it is immediately sent to the pathology lab for DNA extraction. This extracted DNA is then sent to Professor Loose’s team for sequencing using the ROBIN platform. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need," Professor Loose explains. "Methylation is the one we are most interested in early on in this instance because that defines the tumour type." Methylation patterns are crucial epigenetic markers that can differentiate various tumour types, particularly within the complex landscape of brain cancers.
Expert Endorsements and Transformative Potential
The medical community has reacted with widespread enthusiasm to this development. Dr. Simon Paine, a Consultant Neuropathologist at NUH, describes the new method as a "game changer," calling it "truly revolutionary." He highlights not only the increase in speed but also the "incredible" degree of accuracy in diagnosis, which is paramount for effective treatment planning.
The implications extend beyond the immediate clinical benefits, promising significant systemic improvements. "Not only is the test more accurate and quicker, but it is also cheaper than current methods," Professor Loose reveals. The estimated cost stands at approximately £450 per person, with potential for further reduction when scaled up. This cost-effectiveness stems from the method’s ability to consolidate multiple separate tests into a single, comprehensive analysis, thereby streamlining the diagnostic process and reducing overall expenditures. Crucially, it delivers results to patients precisely when they are most needed.
Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, emphasizes the profound impact on patient experience and care. "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis," Dr. Newman states. He also highlights the broader implications for healthcare equity: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis."
Looking Ahead: National Rollout and Personalised Medicine
The Nottingham team is now focused on the crucial next step: rolling out this innovative testing method across NHS Trusts throughout the UK. This national implementation would democratize access to rapid, precise brain tumour diagnostics, ensuring that patients across the country benefit from this advanced technology, regardless of their geographical location. The current reliance on centralized labs for complex genetic testing often creates disparities in access and turnaround times, a challenge that localized, rapid sequencing could overcome.
Furthermore, this technological advancement is already being leveraged in broader research initiatives. The BRAIN MATRIX Trial, a significant study funded by The Brain Tumour Charity, is actively exploring how this technology can effectively match patients to personalised clinical trials across the UK. By providing a rapid and accurate molecular diagnosis, the method enables quicker identification of patients who would benefit most from specific experimental therapies, thereby accelerating the development of new treatments and fostering a more tailored approach to brain cancer care. This integration of diagnostics with clinical trials represents a pivotal step towards precision medicine in neuro-oncology.
The development in Nottingham represents not just a scientific achievement but a beacon of hope for thousands of brain tumour patients. By dramatically shortening diagnostic times, enhancing accuracy, reducing costs, and paving the way for more informed and personalized treatments, this ultra-rapid genetic sequencing method stands poised to fundamentally redefine the standard of care for brain tumours, offering patients a faster path to clarity and potentially, to recovery.
